CME vs REPL · P/E 22, rev $6.52B vs $825.7M cap
CME Group Inc (CME) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
CME Group Inc (CME) is a financial data & stock exchanges company listed on NASDAQ.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported CME revenue for 2025-12-31 was $6.52B. Net income was $4.07B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. CME currently screens at market cap $91.25B and trailing P/E 21.9.
REPL does not have a complete income-statement cache yet.
CME currently screens at market cap $91.25B and trailing P/E 21.9. REPL currently screens at market cap $825.7M.
Not investment advice. Open the CME and REPL stock pages for the full models.
Not investment advice.